ElevateBio's Next-Generation Sequencing Core: Meeting The Challenges Of Cost, Time And Data Quality With Expertise And Collaboration

By Adriana Geldart, Ph.D., Senior Director, Next-Generation Sequencing, ElevateBio

Next-generation sequencing (NGS) has become a cornerstone of modern therapeutic development, particularly in the cell and gene therapy space. By enabling rapid, high-throughput analysis of DNA and RNA, NGS supports everything from process optimization to the detection of on- and off-target gene edits. However, the cost and complexity of building in-house NGS capabilities can be prohibitive, especially for startups and smaller biotechs.

ElevateBio’s internal NGS core was established to address these challenges head-on. By insourcing sequencing capabilities, the organization has reduced turnaround times, improved data quality, and lowered analysis costs, while maintaining the flexibility to meet the evolving needs of R&D teams and partners. This approach not only enhances scientific agility but also provides critical infrastructure to companies that may not have the resources to invest in their own sequencing labs.

Explore how ElevateBio’s NGS services are designed to meet industry demands while fostering collaboration and innovation. It also outlines the unique advantages of an internal NGS model and how it supports the broader biotech ecosystem.